April 28, 2017
Recommended Topic Related To:


"The findings, published online April 4 and in the May issue of Obstetrics Gynecology, should reassure physicians who are reluctant to prescribe HT in these patients out of concern it might increase the risk for recurrence and reduce surviv"...



(olaparib) Capsules


Olaparib is an inhibitor of the mammalian polyadenosine 5’-diphosphoribose polymerase (PARP) enzyme.

The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)one and it has the following chemical structure:

LYNPARZA™ (olaparib) Structural Formula Illustration

The empirical molecular formula for Lynparza is C24H23FN4O3 and the relative molecular mass is 434.46.

Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility of approximately 0.1 mg/mL across the physiological pH range.

Lynparza is available in 50 mg capsules for oral administration. Each capsule contains olaparib as the active ingredient and the following inactive ingredients:

  • Capsule content: lauroyl polyoxylglycerides
  • Capsule shell: hypromellose, titanium dioxide, gellan gum, potassium acetate
  • Capsule printing ink: shellac, ferrosoferric oxide

Last reviewed on RxList: 2/9/2017
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.